ADMA Biologics, Inc. logo ADMA - ADMA Biologics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 8
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $21.00 DETAILS
HIGH: $24.00
LOW: $18.00
MEDIAN: $21.00
CONSENSUS: $21.00
UPSIDE: 154.85%

About ADMA Biologics, Inc. (https://www.admabiologics.com)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Key Executives

NAME TITLE DOB SALARY
Adam S. Grossman Co-Founder, President, Chief Executive Officer & Director 1977 $2,137,334 USD
Kaitlin Kestenberg Chief Operating Officer & Senior Vice President of Compliance 1987 $988,659 USD
Brad Tade Consultant 1974 $823,645 USD
Jerrold Grossman Co-Founder & Vice Chairman of the Board 1948 $90,000 USD
Terence Kohler Chief Financial Officer & Treasurer $46,973 USD
John Hafl Executive Director of Sales
Michael Goldstein General Counsel
Skyler Bloom Senior Director of Business Development & Corporate Strategy

Company Peers

Peer analysis pending, check back in 1-2 minutes.